DCPrime
Pioneering cancer vaccines, DCPrime leverages its DCOne® dendritic cell technology to develop innovative immunotherapies. Their lead candidate, DCP-001, is currently in a Phase 2 study for Acute Myeloid Leukemia (AML), building on promising Phase 1 results. With Orphan Medicinal Product designation in the EU, DCPrime aims to provide effective treatments for hematological cancers, including Multiple […]
Skyline Dx
Skyline Dx is a molecular diagnostics company focusing on oncology and infectious diseases. Their platform-agnostic tests range from PCR to Next Generation Sequencing technologies. Skyline Dx partners with discovery and commercial companies to develop and distribute their diagnostic tests. The company is dedicated to advancing precision medicine through innovative molecular diagnostics.
SigmaSreening
SigmaScreening has developed a mammography device that reduces pain and improves diagnostic accuracy. Founded by Amsterdam UMC professors, the company aims to enhance breast cancer detection with their patented technology. SigmaScreening has licensed their technology to Teledyne, who continue development of the device.
Kling Biotherapeutics
Discovering antibody-based therapeutics, Kling Biotherapeutics targets cancer and infectious diseases. Their platform leverages patient immune repertoires to identify novel therapeutic targets. Kling Biotherapeutics has a rich pipeline of antibodies for oncology and infectious disease applications in clinical and preclinical development.
Ellogon.ai
Ellogon’s AI-driven cancer diagnostics solution quantifies oncology biomarkers in complex histopathological slides with limited annotations. Traditional supervised deep learning requires exhaustive annotation by pathologists, which is impractical due to the enormous size and complexity of histopathology slides. Ellogon however, uses sparse-shot learning to achieve high accuracy with significantly fewer annotations, making it a game-changer in […]
CRCbioscreen
Innovating colorectal cancer screening, CRCbioscreen develops stool-based tests to detect high-risk precursor lesions. Their research, led by experts from the Netherlands Cancer Institute and based on Amsterdam UMC technology, aims to improve early cancer detection. CRCbioscreen’s tests could potentially replace current national screening programs. The company is committed to advancing oncology diagnostics through innovative biomarker […]
AlpENa Biosciences
Innovating cancer therapeutics, AlpENa Biosciences develops bispecific antibodies that activate immune cells to target and destroy tumor cells. Their research, based on the work of Professor Marjolein van Egmond, shows promising potential in a variety of oncology treatments. The company is backed by Versant Ventures in order to advance these therapies.
